In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Covidien - Back on Top: An Interview with Richard Meelia

Executive Summary

Is there a medical device company today doing better than Covidien? The company is making a huge splash building new businesses and shoring up existing ones. But Covidien, formerly Tyco, hasn't always had it so good. A corporate scandal in the early 2000s brought Tyco's corporate management down and scuttled the healthcare business' strategic plan. After years of sitting on the sidelines, Covidien is back, stronger than ever.

Related Content

PEAK Cuts Into The Competitive Electrosurgery Market
Device M&A Poised For A Strong Year
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010
Covidien - Back on Top: An Interview with Richard Meelia
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Covidien Set to Compete in Vascular Business
ev3: The Virtues of Focus
Tyco Healthcare: Surviving Scandal
Whither Tyco? Whither Hospital Supply?
Tyco Takes a Huge Step Forward with US Surgical Acquisition


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts